Spinifex Pharma names new CMO
This article was originally published in Scrip
Spinifex Pharmaceuticals, a pain drug development company, has appointed Dr Ronald Marcus chief medical officer – effective immediately. He joins the Melbourne, Australia-based firm from Bristol-Myers Squibb, where he held a number of senior leadership positions within the drugmaker's neuroscience division. At Spinifex Dr Marcus will be responsible for developing the firm's lead candidate, chronic pain drug EMA401, and the company's pre-clinical pipeline.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.